By targeting ROR1, these therapies can disrupt specific oncogenic signaling pathways that cancer cells depend on for survival, proliferation, and metastasis, potentially offering durable remissions and improved outcomes for patients with aggressive malignancies. This evidence concerns the gene ROR1 and cancer.